Holen Sie sich die Stockscreener-App
4.52
6.60%
0.28
Vorhandelsmarkt:
4.50
-0.02
-0.44%
Schlusskurs vom Vortag:
$4.24
Offen:
$4.27
24-Stunden-Volumen:
77,709
Relative Volume:
2.11
Marktkapitalisierung:
$12.22M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-10.69M
KGV:
-0.6383
EPS:
-7.0818
Netto-Cashflow:
$-9.07M
1W Leistung:
+12.02%
1M Leistung:
+19.89%
6M Leistung:
-54.23%
1J Leistung:
-38.73%
1-Tages-Spanne:
$4.255
$4.55
1-Wochen-Bereich:
$3.93
$4.55
52-Wochen-Spanne:
$3.51
$43.50
Intensity Therapeutics Inc Stock (INTS) Company Profile
Firmenname
Intensity Therapeutics Inc
Sektor
Branche
Telefon
203-221-7381
Adresse
1 ENTERPRISE DRIVE, SUITE 430, SHELTON
Compare INTS vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
INTS
Intensity Therapeutics Inc
|
4.52 | 11.08M | 0 | -10.69M | -9.07M | -7.0818 |
VRTX
Vertex Pharmaceuticals Inc
|
529.59 | 126.07B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
649.81 | 65.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
916.80 | 57.70B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
313.04 | 40.19B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
189.99 | 39.82B | 742.00K | -1.37B | -1.07B | -7.0731 |
Intensity Therapeutics Inc Aktie (INTS) Neueste Nachrichten
Form 4 Intensity Therapeutics Inc For: 1 July By Investing.com - Investing.com Canada
ESPP purchase adds shares for Intensity Therapeutics (NASDAQ: INTS) officer - Stock Titan
Intensity Therapeutics (INTS) CFO adds 1,093 ESPP shares at discount - Stock Titan
Intensity Therapeutics updates INT230-6 cancer trials - grafa.com
Intensity Therapeutics Provides Mid-Year Update Highlighting Late-Stage Development Programs and Strategic Partnering Opportunities for INT230-6 - PR Newswire
Why Did INTS Stock Plummet 25% Today? - Stocktwits
Price to sales forward of Intensity Therapeutics, Inc. – NASDAQ:INTS - TradingView
Price to earnings forward of Intensity Therapeutics, Inc. – NASDAQ:INTS - TradingView
Enterprise value to EBITDA forward of Intensity Therapeutics, Inc. – NASDAQ:INTS - TradingView
Intensity Therapeutics, Inc. Actuals & Estimates (NASDAQ:INTS) - TradingView
Enterprise value to revenue forward of Intensity Therapeutics, Inc. – NASDAQ:INTS - TradingView
INTS Forecast — Price Target — Prediction for 2027 - TradingView
Intensity Therapeutics Inc (INTS) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Intensity Therapeutics Inc (INTS) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Intensity Therapeutics Inc (INTS) Institutional Confidence - TradingKey
Intensity Therapeutics Inc (INTS) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Intensity Therapeutics Inc (INTS) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Intensity Therapeutics Inc (INTS) Valuation: PE, PB & Fair Value Analysis - TradingKey
Intensity Therapeutics Stockholders Approve Proposals at Annual Meeting - The Globe and Mail
Intensity Therapeutics Inc (INTS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Intensity Therapeutics Inc (INTS) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Intensity Therapeutics Inc (INTS) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Intensity Therapeutics shareholders approve board proposals at annual meeting By Investing.com - Investing.com Nigeria
Intensity Therapeutics shareholders approve board proposals at annual meeting - Investing.com
Intensity Therapeutics (NASDAQ: INTS) OKs share plan increases and board elections - Stock Titan
INTS: All proposals, including director elections and stock plan amendments, were approved by majority vote - TradingView
INTS Q1 2026 Earnings: Narrower-than-Expected Loss Surprises as Clinical Progress ContinuesROE Trend Analysis - dars.gov.et
Intensity Therapeutics (INTS) Shows Modest Decline, Holds Above Key SupportBear Flag - newsline.com
Intensity Therapeutics (INTS) Edges Lower as Stock Holds Near Key SupportIchimoku Kumo Break - newsline.com
Intensity_Therapeutics - Westfair Communications
Intensity Therapeutics (INTS) Slips 5.75% as Selling Pressure Intensifies Near Key Support LevelValue Stock Ideas - newsline.com
Intensity Therapeutics Inc (INTS) Stock Price, Quote, News & History - Benzinga
INTS News | INTENSITY THERAPEUTICS INC (NASDAQ:INTS) - ChartMill
INTS Technical Analysis | Trend, Signals & Chart Patterns | INTENSITY THERAPEUTICS INC (NASDAQ:INTS) - ChartMill
Intensity Therapeutics Inc. (INTS) upgraded to buy: Here's why - MSN
INTS | Intensity Therapeutics, Inc. Common Insider Trading - Quiver Quantitative
INTS Q1 2026 Earnings: Narrower-Than-Expected Loss as Pre-Revenue Biotech Advances Clinical PipelineEPS Surprise History - The Legal Advocate
Intensity Therapeutics Inc. (INTS) Upgraded to Buy: Here's Why - Yahoo Finance
INTSIntensity Therapeutics Inc Stock Price and Quote - Finviz
INTS Q1 2026 Earnings: EPS Beat Despite Pre-Revenue Status; Shares Edge HigherRevenue Inflection Point - The Legal Advocate
Intensity Therapeutics Inc. (INTS) upgraded to buy: Here's what you should know - MSN
INTS Stock Price, Quote & Chart | INTENSITY THERAPEUTICS INC (NASDAQ:INTS) - ChartMill
Benchmark reiterates Intensity Therapeutics stock rating on clinical progress By Investing.com - Investing.com South Africa
Benchmark reiterates Intensity Therapeutics stock rating on clinical progress - Investing.com India
Intensity Therapeutics shares plunge 30% after $4 million discounted stock offering - MSN
Intensity Therapeutics Recognized with GHP Magazine's 2026 Healthcare & Pharmaceutical Award - ChartMill
Intensity Therapeutics Inc. (INTS) could find a support soon, here's why you should buy the stock now - MSN
How Intensity (INTS) maintains its competitive edge | Q4 2025: Earnings UnderperformMomentum Pick - Newser
Dyne Therapeutics (DYN) Upgraded to Buy: Here's What You Should Know - Yahoo Finance
A. G. P. Maintains Intensity Therapeutics(INTS.US) With Buy Rating, Maintains Target Price $30 - Moomoo
How Intensity (INTS) talent strategy drives results | Q1 2026: Profit Exceeds ViewsAdjusted Earnings Analysis - Newser
Finanzdaten der Intensity Therapeutics Inc-Aktie (INTS)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.05%
0.74%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):